Skip to main content
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. — Investor Relations & Filings

Ticker · LENZ ISIN · US38870X1046 US Manufacturing
Open in API
Filings indexed 329 across all filing types
Latest filing 2022-08-11 Interim / Quarterly Rep…
Country US United States of America
Listing US LENZ

About LENZ Therapeutics, Inc.

https://lenz-tx.com/

LENZ Therapeutics, Inc. is a late-stage pharmaceutical company focused on developing and commercializing ophthalmic therapies to improve vision. Its primary product is VIZZ™ (aceclidine ophthalmic solution) 1.44%, an FDA-approved eye drop for the treatment of presbyopia, the age-related loss of near vision. VIZZ is the first aceclidine-based therapy for this condition, which affects an estimated 1.8 billion people globally. The product is designed to restore near vision, providing a pharmaceutical alternative to reading glasses for a broad patient population.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2022
2022-08-11 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and references a press release announcing financial results for the quarter ended June 30, 2022. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes a press release as an exhibit. The length is 3684 characters, which is relatively short and consistent with a report announcing or furnishing information rather than the full financial report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report announcing financial results but not the full earnings release or quarterly report itself. The press release is attached as an exhibit, and the document states the information is "furnished" and not "filed," indicating it is not the full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-08-11 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes a press release about dosing the first patient with an investigational therapy, attached as an exhibit. The document is short (3093 characters) and primarily serves as an announcement of an event rather than a detailed financial report or earnings release. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-08-11 English
Regulatory Filings 2022
Regulatory Filings
2022-07-29 English
Regulatory Filings 2022
Regulatory Filings
2022-07-26 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter from Graphite Bio, Inc. to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It references Rule 461 under the Securities Act of 1933 and discusses the timing of the registration statement becoming effective. The document is short (1417 characters) and is a formal correspondence related to a regulatory filing process, not a financial report or detailed disclosure. It does not contain financial data, management discussion, or report content. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-07-26 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.